HEMABATE (carboprost tromethamine) by Pfizer is clinical pharmacology carboprost tromethamine administered intramuscularly stimulates in the gravid uterus myometrial contractions similar to labor contractions at the end of a full term pregnancy. Approved for postpartum hemorrhage due to uterine atony which has not responded to conventional methods of management. First approved in 1979.
Drug data last refreshed 2d ago · AI intelligence enriched 2w ago
HEMABATE (carboprost tromethamine) is a prostaglandin analog administered intramuscularly that stimulates myometrial contractions to evacuate uterine contents and provide hemostasis. It is indicated for postpartum hemorrhage due to uterine atony that has not responded to conventional management. The drug works by directly stimulating smooth muscle contraction in the gravid uterus, similar to labor contractions.
Legacy product with declining market exclusivity; career growth opportunities are limited as the brand transitions toward loss of exclusivity.
CLINICAL PHARMACOLOGY Carboprost tromethamine administered intramuscularly stimulates in the gravid uterus myometrial contractions similar to labor contractions at the end of a full term pregnancy. Whether or not these contractions result from a direct effect of carboprost on the myometrium has not…
Worked on HEMABATE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on HEMABATE offers limited career growth due to its mature lifecycle and approaching loss of exclusivity. Roles focus on defending market share, managing generic transition, and supporting legacy brand operations rather than expansion or innovation.